Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-11-15 | VERTEX PHARMACEUTICALS INC / MA | ALTSHULER DAVID
(EVP, Chief Scientific Officer) |
S | Common Stock | D | 15 | $478.56 - $478.56 | $7,178 |
| 2024-11-08 | VERTEX PHARMACEUTICALS INC / MA | Kewalramani Reshma
(CEO & President) |
S | Common Stock | D | 15198 | $515.00 - $515.00 | $7,826,970 |
| 2024-08-08 | VERTEX PHARMACEUTICALS INC / MA | Bhatia Sangeeta N.
(Director) |
S | Common Stock | D | 1292 | $466.29 - $466.29 | $602,446 |
| 2024-08-08 | VERTEX PHARMACEUTICALS INC / MA | Bhatia Sangeeta N.
(Director) |
M | Common Stock | A | 1292 | $152.74 - $152.74 | $197,340 |
| 2024-08-07 | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen
(EVP and CMO) |
S | Common Stock | D | 2280 | $476.75 - $476.75 | $1,086,990 |
| 2024-07-30 | VERTEX PHARMACEUTICALS INC / MA | Kewalramani Reshma
(CEO & President) |
S | Common Stock | D | 15202 | $505.00 - $505.00 | $7,677,010 |
| 2024-07-24 | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen
(EVP and CMO) |
S | Common Stock | D | 2280 | $488.46 - $488.46 | $1,113,688 |
| 2024-07-22 | VERTEX PHARMACEUTICALS INC / MA | Kewalramani Reshma
(CEO & President) |
S | Common Stock | D | 15202 | $497.00 - $497.00 | $7,555,394 |
| 2024-07-10 | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen
(EVP and CMO) |
S | Common Stock | D | 2280 | $487.34 - $487.34 | $1,111,135 |
| 2024-06-12 | VERTEX PHARMACEUTICALS INC / MA | Atkinson Edward M...
(EVP, Chief Technical Ops. Off.) |
S | Common Stock | D | 7288 | $478.00 - $478.00 | $3,483,664 |
| 2024-06-11 | VERTEX PHARMACEUTICALS INC / MA | Atkinson Edward M...
(EVP, Chief Technical Ops. Off.) |
F | Common Stock | D | 6824 | $481.96 - $481.96 | $3,288,895 |
| 2024-06-05 | VERTEX PHARMACEUTICALS INC / MA | Sachdev Amit
(EVP Chief Patient & Ext Af Off) |
G | Common Stock | D | 4600 | $0.00 - $0.00 | $0 |
| 2024-06-03 | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania
(EVP, Chief Reg. & Quality Off.) |
S | Common Stock | D | 2175 | $460.00 - $460.00 | $1,000,500 |
| 2024-05-30 | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania
(EVP, Chief Reg. & Quality Off.) |
S | Common Stock | D | 4600 | $439.11 - $445.00 | $2,033,158 |
| 2024-05-28 | VERTEX PHARMACEUTICALS INC / MA | WAGNER CHARLES F JR
(EVP & Chief Financial Officer) |
S | Common Stock | D | 3250 | $454.79 - $454.79 | $1,478,067 |
| 2024-05-24 | VERTEX PHARMACEUTICALS INC / MA | Kewalramani Reshma
(CEO & President) |
S | Common Stock | D | 1565 | $457.00 - $457.00 | $715,205 |
| 2024-05-24 | VERTEX PHARMACEUTICALS INC / MA | Kewalramani Reshma
(CEO & President) |
M | Common Stock | A | 1565 | $187.53 - $187.53 | $293,484 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |